CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7250
+0.0150 (+0.55%)
As of 2:29PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.7100
Open2.6900
Bid2.7100 x 800
Ask2.7200 x 1000
Day's Range2.6450 - 2.7350
52 Week Range2.4500 - 6.9000
Volume153,721
Avg. Volume336,387
Market Cap146.537M
Beta (3Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-2.2250
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • American City Business Journals

    These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

    While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?

  • Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study
    Zacks

    Calithera (CALA) Completes Enrollment in Mid-Stage RCC Study

    Calithera (CALA) completes patient enrollment in a phase II study evaluating a combination regimen of its lead candidate, telaglenastat, in patients with advanced kidney cancer.

  • GlobeNewswire

    Calithera Biosciences Completes Patient Enrollment in Randomized CANTATA Trial of Telaglenastat and Cabozantinib in Advanced Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has completed patient enrollment in the ongoing CANTATA trial. CANTATA is a global, randomized double-blind clinical trial of the glutaminase inhibitor telaglenastat (CB-839) combined with cabozantinib, a standard of care, in patients with advanced or metastatic renal cell carcinoma (RCC) who have received one or two prior treatments. Exelixis, Inc. is providing cabozantinib for the trial through a material supply agreement with Calithera.

  • GlobeNewswire

    Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that new data from its research and development portfolio will be featured in two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10. “The preclinical IL4I1 immuno-oncology program is an exciting new addition to our pipeline, and we are pleased that initial data from this program, as well as our ongoing CB-708 preclinical program, have been accepted for presentation at this high-profile meeting,” said Susan Molineaux, PhD, president and chief executive officer of Calithera.

  • GlobeNewswire

    New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced the presentation of new data from the investigational first-in-class oral arginase inhibitor INCB001158 as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab in microsatellite stable (MSS) colorectal carcinoma patients. The data were presented during an oral Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2019 taking place in Barcelona, Spain (Abstract #440O).

  • GlobeNewswire

    Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, presented today supporting data for its previously reported positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The telaglenastat-everolimus combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile.

  • Calithera Biosciences Enters Oversold Territory
    Zacks

    Calithera Biosciences Enters Oversold Territory

    Calithera Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    Calithera to Host Webcast Conference Call for Analysts and Investors During European Society for Medical Oncology (ESMO) Congress 2019

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel.

  • Implied Volatility Surging for Calithera (CALA) Stock Options
    Zacks

    Implied Volatility Surging for Calithera (CALA) Stock Options

    Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

  • GlobeNewswire

    Calithera to Present at the 2019 Cantor Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the 2019 Cantor Global Healthcare Conference at 1:45 p.m. ET on Friday, October 4, 2019 in New York. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

  • Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast?
    Simply Wall St.

    Calithera Biosciences, Inc. (NASDAQ:CALA): Is It Growing Too Fast?

    As the US$213m market cap Calithera Biosciences, Inc. (NASDAQ:CALA) released another year of negative earnings...

  • Thomson Reuters StreetEvents

    Edited Transcript of CALA earnings conference call or presentation 8-Aug-19 9:00pm GMT

    Q2 2019 Calithera Biosciences Inc Earnings Call

  • GlobeNewswire

    Calithera to Participate in Wells Fargo Healthcare Conference and Citi 14th Annual Biotech Conference

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in September. Susan M. Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present in Boston on Wednesday, September 4, 2019, at 1:50 p.m. Eastern Time. Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity.

  • Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Pay Justified?
    Simply Wall St.

    Is Calithera Biosciences, Inc.'s (NASDAQ:CALA) CEO Pay Justified?

    Susan Molineaux has been the CEO of Calithera Biosciences, Inc. (NASDAQ:CALA) since 2010. This report will, first...

  • GlobeNewswire

    Calithera Biosciences Reports Second Quarter 2019 Financial Results and Recent Highlights

    --Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 -- Calithera.

  • GlobeNewswire

    Calithera Biosciences to Report Second Quarter 2019 Financial Results on Thursday, August 8, 2019

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s second quarter 2019 financial results will be released on Thursday, August 8, 2019. Company management will host a conference call on Thursday, August 8, 2019 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • Does Calithera Biosciences, Inc. (NASDAQ:CALA) Have A High Beta?
    Simply Wall St.

    Does Calithera Biosciences, Inc. (NASDAQ:CALA) Have A High Beta?

    If you're interested in Calithera Biosciences, Inc. (NASDAQ:CALA), then you might want to consider its beta (a measure...

  • GlobeNewswire

    Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib

    Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with Pfizer’s CDK 4/6 inhibitor palbociclib, also known as Ibrance®.

  • GuruFocus.com

    Calithera Biosciences Inc (CALA) PRESIDENT AND CEO Susan Molineaux Bought $200,208 of Shares

    PRESIDENT AND CEO of Calithera Biosciences Inc (NASDAQ:CALA) Susan Molineaux bought 51,600 shares of CALA on 06/25/2019 at an average price of $3.88 a share.

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., June 21, 2019 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel.

  • Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain?
    Simply Wall St.

    Did You Miss Calithera Biosciences's (NASDAQ:CALA) 37% Share Price Gain?

    While Calithera Biosciences, Inc. (NASDAQ:CALA) shareholders are probably generally happy, the stock hasn't had...

  • GlobeNewswire

    Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it intends to offer and sell 10,000,000 shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. In connection with this offering, Calithera expects to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock.

  • Benzinga

    Calithera's Kidney Cancer Drug Doubles Progression-Free Survival Vs. Chemotherapy

    Calithera, which develops novel small molecule therapies for cancer and other life-threatening diseases, announced positive top-line results from a Phase 2 study dubbed ENTRATA that is evaluating telaglenastat, or CB-839, in combination with the chemotherapy drug everolimus in patients with renal cell carcinoma. The enrollees demonstrated that the evaluated combo treatment doubled the median progress-free survival to 3.8 months compared to 1.9 months for everolimus alone, Calithera said. The risk of disease progression or death was also reduced by 36% in the combo treatment arm.

  • GlobeNewswire

    Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced positive results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat (CB-839) in combination with everolimus in patients with advanced renal cell carcinoma (RCC). The combination doubled the median progression-free survival (PFS) in heavily pre-treated patients with advanced RCC and had a well-tolerated safety profile. Telaglenastat is the first glutaminase inhibitor to demonstrate clinical activity for the treatment of cancer.